Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mochida Pharma Anti-Depression Drug MHD-55 Enters Phase III Trial

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Mochida Pharma announced that anti-depression drug MHD-55 (escitalopram) has entered Phase III trials. The company's pulmonary arterial hypertension drug MD-0701 (treprostinil), and a cell drug jointly developed with Japan Chemical Research Pharma will enter clinic trials this year. Mochida also plans to start Beselna Cream (imiquimod) clinic trials for additional applications of treating solar kerasotes. Currently imiquimod is a therapeutic agent for condyloma acuminatum. As part of its growth strategy, Mochida has been actively seeking and in-licensing products that have been marketed overseas to add to the company's product lineup. (Click here for more - Japanese language)

You may also be interested in...

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.

EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions

The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts